8-K: Aquestive Therapeutics Resubmits Anaphylm NDA, Advances Pipeline

Aquestive Therapeutics announced the resubmission of its New Drug Application for Anaphylm and provided updates on its AQST-108 topical gel for atopic dermatitis.

Summary

• Aquestive Therapeutics has resubmitted its New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film to the U.S. Food and Drug Administration (FDA) on September 17, 2026, addressing issues from a Complete Response Letter (CRL) dated January 30, 2026.
• The company is requesting expedited review for Anaphylm and anticipates potential ex-US filings in Canada by the end of 2026 and in the European Union in Q1 2027.
• Aquestive is also advancing its AQST-108 (epinephrine) topical gel, targeting atopic dermatitis (AD) as an initial indication, with potential for other dermatologic and immunologic applications.
• The company reported $98.5 million in cash and cash equivalents as of June 30, 2026, with access to additional funding contingent on Anaphylm's FDA approval.
• The presentation highlights the potential of Anaphylm as a needle-free, orally delivered epinephrine alternative and AQST-108's novel approach to localized treatment of inflammatory skin conditions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic update, primarily driven by the resubmission of the Anaphylm NDA and the potential of the AQST-108 pipeline, despite past regulatory setbacks.

Positives

• NDA resubmission for Anaphylm addresses FDA concerns from the January 30, 2026 CRL.
• Anaphylm is positioned as a novel, needle-free, orally delivered epinephrine product.
• AQST-108 topical gel shows potential for localized treatment of atopic dermatitis and other skin conditions.
• The company has $98.5 million in cash and cash equivalents as of June 30, 2026.
• Access to $75 million in strategic funding and $20 million under a debt facility is available upon Anaphylm FDA approval.
• Ex-US filings for Anaphylm are on track for Canada (end of 2026) and EU (Q1 2027).

Negatives

• The FDA previously issued a Complete Response Letter (CRL) for Anaphylm on January 30, 2026, indicating deficiencies.
• There is no guarantee that the FDA will grant expedited review for Anaphylm.
• The FDA's classification of the NDA resubmission and the resulting review timeline are uncertain.
• Early-stage results for AQST-108 may not predict future clinical outcomes or regulatory approval.

Risks

• The FDA may determine the Anaphylm NDA resubmission does not fully address the CRL.
• The FDA may refuse to file or accept the resubmitted NDA for review.
• The FDA's review period for Anaphylm could be longer than anticipated.
• Expedited review for Anaphylm may not be granted.
• Human factors, pharmacokinetic, or pharmacodynamic study results may differ from final analyses or be interpreted differently by the FDA.
• The FDA may request additional information, analyses, or studies for Anaphylm.
• Risks associated with the commercial launch of Anaphylm, including market acceptance and competition.
• Development of AQST-108 may require additional studies and may not result in regulatory approval or a commercially viable product.

Future Outlook

The company is focused on the FDA review of the Anaphylm NDA, potential ex-US filings, and the advancement of AQST-108 for atopic dermatitis. Funding is available contingent on Anaphylm approval.

Management Comments

• Anaphylm will be the first and only non-device-based, orally delivered epinephrine product and may be accepted by patients, prescribers and payors as an alternative to existing standards of care, if approved by the FDA.
• AQST-108 has the potential to reduce inflammation and itch.
• The company is building its commercial infrastructure for Anaphylm.

Industry Context

StockSavvy.ai notes that the resubmission of the Anaphylm NDA comes at a time when the epinephrine market is growing, with significant unmet needs in anaphylaxis treatment due to challenges with existing auto-injectors. The development of AQST-108 also aligns with the increasing focus on novel treatments for atopic dermatitis.

Comparison to Industry Standards

• The epinephrine market is projected to reach approximately $2.03 billion by 2029, with Anaphylm aiming to capture a significant share with its novel delivery system.
• Current epinephrine auto-injectors (EAIs) face challenges including inconvenient size, social stigma, complicated administration, and needle phobia, which Anaphylm aims to overcome.
• In the atopic dermatitis market, Anaphylm's competitor landscape includes topical creams and other treatments with varying efficacy and safety profiles. AQST-108 aims to offer a unique mechanism of action with localized effects.
• The market for branded topicals in dermatology is substantial, with projected revenues for products like Opzelura and Vtama in the hundreds of millions, indicating a strong market for effective new treatments.

Stakeholder Impact

• Shareholders: Potential for significant value creation if Anaphylm is approved and commercialized successfully, and if AQST-108 progresses as planned.
• Patients: Potential for improved treatment options for anaphylaxis with Anaphylm and for atopic dermatitis with AQST-108.
• Payers: Need to evaluate Anaphylm and AQST-108 for formulary inclusion and reimbursement.
• Prescribers: Will need to assess the clinical profile and benefits of Anaphylm and AQST-108 for their patients.

Next Steps

• FDA review of the Anaphylm NDA resubmission.
• Potential expedited review for Anaphylm.
• Ex-US filings for Anaphylm in Canada and the European Union.
• Continued clinical development and regulatory engagement for AQST-108.
• Preparation for potential commercial launch of Anaphylm.

Key Dates

Recommendation

The resubmission of the Anaphylm NDA is a positive step, but the past CRL introduces uncertainty. The potential of AQST-108 is promising but still in development. The company's cash position and contingent funding provide some runway, but approval timelines and market adoption remain key variables. A 'hold' reflects the balance of potential upside against existing regulatory and development risks.

Keywords

Anaphylm, AQST-108, epinephrine, anaphylaxis, atopic dermatitis, sublingual film, topical gel, FDA